Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. Its entire published human record is three volunteers dosed for pigmentation in 1996 and twenty men dosed for erectile function in two crossover studies — and every one of those studies used roughly 0.025 mg/kg, about 1,750 mcg for a 70 kg adult, several times the fixed amounts the research market quotes. This guide covers what the record contains, what it does not, and the published case literature. Research-use educational reference only.
Standard Access: This compound's three paid filesAll-Access Lifetime: all 55 guides + every printableEducational content only
Melanotan II Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Melanotan II at a glance
What it is
Synthetic cyclic heptapeptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 — a lactam-bridged analog of alpha-MSH(4-10) and a non-selective melanocortin receptor (MC1R–MC5R) agonist
Identity
PubChem CID 92432 · C50H69N15O9 · 1024.2 g/mol · CAS 121062-08-6 · UNII UPF5CJ93X7. Verified against the PubChem substance record, not vendor literature
Human efficacy evidence
Three studies, twenty-three subjects in total. Pigmentation: 2 of 3 male volunteers in a 1996 pilot (PMID 8637402). Erectile function: 20 men across two double-blind placebo-controlled crossover studies (PMIDs 9679884, 11018622)
What those studies actually dosed
0.01–0.03 mg/kg in the pigmentation pilot and 0.025 mg/kg in both erectile-function studies — roughly 1,750 mcg for a 70 kg adult, several times the fixed amounts quoted in community protocols
Plasma half-life
Not established in humans. No human pharmacokinetic study of Melanotan II is indexed in PubMed; the widely quoted “30 minutes to an hour” belongs to a different molecule's human data. See the half-life section
Registered trials
None genuine. ClinicalTrials.gov holds exactly one record naming Melanotan II (NCT07437560), and its own brief summary opens by calling itself an example record
Regulatory status
Not FDA-approved for any use; sold as research-only; unapproved in US/UK/EU
Documented harms
Eruptive and darkening melanocytic nevi, melanoma and melanoma in situ, priapism, rhabdomyolysis and renal infarction, each in named published case reports — listed with citations below
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
What it is / mechanism
Melanotan II is a lactam-bridged cyclic analog of the alpha-melanocyte-stimulating hormone fragment alpha-MSH(4-10), with the structure Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2. Two features of that structure explain its pharmacology. The D-phenylalanine substitution at position 7 and the norleucine at position 4 are the same two modifications that made [Nle4, D-Phe7]-alpha-MSH superpotent, and the side-chain-to-side-chain lactam bridge between Asp5 and Lys10 locks the message sequence into the bioactive turn conformation and resists enzymatic breakdown — which is why it is described in the pharmacology literature as a superpotent and unusually stable agonist. The consequence is that it is a non-selective agonist across the whole melanocortin receptor family (MC1R through MC5R) rather than a selective one. At MC1R on melanocytes, receptor activation raises intracellular cyclic AMP and upregulates tyrosinase, the rate-limiting enzyme of melanin synthesis, driving eumelanin production and skin darkening. Because the same molecule engages MC3R and MC4R in the central nervous system, it also produces the appetite and sexual-arousal effects that distinguish it from the MC1R-selective afamelanotide (Melanotan I); the related fragment bremelanotide (PT-141) was developed specifically around that MC4R sexual-response pathway. The stability that makes MT-II a standard tool for characterising melanocortin receptors in the laboratory is the same property that makes its non-selectivity clinically awkward: there is no way to engage MC1R with this molecule without also engaging the central receptors.
Researched effects
The honest summary of the human effect record is that it is very small and that the two effects it documents are not the same size. Pigmentation: in the 1996 pilot phase-I study, two of three male volunteers showed increased pigmentation of the face, upper body and buttock, measured by quantitative reflectance as well as by visual assessment, one week after a two-week course of daily subcutaneous injections had ended (PMID 8637402). That is the entire published human tanning record for this compound. Erectile response: across two double-blind, placebo-controlled crossover studies in a combined twenty men with erectile dysfunction, Melanotan II initiated erections in 17 of 20 subjects in the absence of sexual stimulation, with a mean of about 41 minutes of RigiScan tip rigidity above 80% versus a placebo figure of 1.9–3.0 minutes, and self-reported sexual desire was higher after Melanotan II than after placebo in 13 of 19 doses versus 4 of 21 (PMIDs 9679884, 11018622, pooled and re-reported in PMID 11035391). Appetite suppression, nausea, and the stretching-and-yawning complex that preceded spontaneous erections were reported across all three studies as effects of the compound, not as incidental observations. Everything beyond these three studies — the loading protocols, the maintenance schedules, the dose-response claims — comes from community reports and vendor literature, not from published research. Individual responses reportedly vary widely with skin type, dose and UV exposure.
Evidence & regulatory status
Pigmentation, the only human tanning study: Dorr et al., Life Sciences 1996;58(20):1777-84 (PMID 8637402) — a single-blind, alternating-day, placebo-controlled pilot in three normal male volunteers, starting at 0.01 mg/kg subcutaneously daily Monday to Friday for two consecutive weeks, with two subjects escalated in 0.005 mg/kg increments to 0.03 mg/kg and one to 0.025 mg/kg. Two of the three showed increased pigmentation by quantitative reflectance one week after dosing ended. The 0.03 mg/kg level produced Grade II somnolence and fatigue (WHO criteria) in one of the two subjects who reached it, and mild nausea was reported at most dose levels. This paper is also where the figure used by every later study comes from: it closes by recommending 0.025 mg/kg/day as the single dose for future phase-I work, which is what both erectile-function studies then used.
Erectile function, study 1: Wessells et al., Journal of Urology 1998;160(2):389-93 (PMID 9679884) — ten men with erectile dysfunction of no known organic cause, double-blind placebo-controlled crossover, real-time RigiScan monitoring over six hours. Clinically apparent erections developed in 8 of 10; mean duration of tip rigidity above 80% was 38.0 minutes versus 3.0 for placebo (p=0.0045), at a dose of 0.025 mg/kg.
Erectile function, study 2: Wessells et al., Urology 2000;56(4):641-6 (PMID 11018622) — ten subjects with organic risk factors, same design and same 0.025 mg/kg dose administered twice. Subjectively reported erections followed 12 of 19 injections versus 1 of 21 placebo doses; mean tip rigidity above 80% was 45.3 minutes versus 1.9 (P=0.047); 4 of 19 injections were associated with severe nausea.
The pooled re-report: Wessells et al., International Journal of Impotence Research 2000;12 Suppl 4:S74-9 (PMID 11035391) is a supplement-issue review of the same twenty men, not a fourth study. It is indexed with a clinical-trial publication type, which is why literature counts of Melanotan II 'trials' overstate the record — the twenty men are counted twice.
No genuine registered trial: a ClinicalTrials.gov search returns exactly one record naming Melanotan II, NCT07437560, listed as recruiting with Hudson Biotech as lead sponsor. Its own brief summary opens 'This example interventional study record describes a randomized Phase 2 clinical trial', so the registry contains no genuine registered study of this compound. Verified against the record itself on 2026-09-10, not against a search-result count.
Regulatory: Melanotan II has no FDA approval for any indication and is not approved in the UK, EU, or other major jurisdictions; regulators (including the FDA and UK MHRA) have issued warnings against unlicensed products.
Research-use: Material sold under this name is intended for laboratory and educational research use only and is not a medicine or cosmetic; nothing here endorses human use.
Research timeline
Dated milestones taken from the primary records: the molecule's discovery, its first registered human study, the trials that shaped the evidence and the regulatory decisions. Each entry links to the record it comes from.
A University of Arizona pilot Phase 1 study gives the cyclic alpha-MSH analogue Melanotan II to three healthy men under the skin: it reports mild nausea, sleepiness and fatigue, a stretching-and-yawning response with spontaneous erections, and increased pigmentation in two of the three. PMID 8637402
A double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction reports erections in 8 of 10 after Melanotan II, with nausea, stretching, yawning and reduced appetite more frequent than after placebo. PMID 9679884
A case report describes systemic toxicity with sympathomimetic excess and rhabdomyolysis (muscle breakdown) in a man who injected Melanotan II bought online to darken his skin; he needed intensive-care admission. PMID 23121206
Annals of Internal Medicine publishes a report linking melanotan use to posterior reversible encephalopathy syndrome (PRES), a brain-swelling syndrome. PMID 23648958
A Danish case report describes melanoma in a 20-year-old woman three months after a course of self-injected Melanotan II combined with sunbed use; the authors note that the extent and types of its adverse effects are unknown because it is unlicensed and incompletely tested. PMID 24355990
FDA's page on compounding safety risks, as updated on this date, lists Melanotan II among substances that had been in Category 2 and whose nominations were withdrawn, citing published case reports of melanoma, PRES, sympathomimetic toxicity and priapism. FDA · compounding safety risks, Apr 22, 2026
Records checked Oct 4, 2026
Claims at a glance
The claims most often made about this compound, each with the strongest kind of evidence we found for it. The grade says what was studied, not whether the claim is true; the line beside it says what that study showed.
Tans the skin without sunHuman, non-randomised. The only pigmentation study had three volunteers, two of whom tanned (1996); the controlled tanning trials often cited used a different molecule, afamelanotide. PMID 8637402
Produces erectionsHuman, non-randomised. A placebo-controlled crossover in 10 men with psychogenic erectile dysfunction: erections in 8 of 10, with far longer rigidity than on placebo. PMID 9679884
Increases sexual desireHuman, non-randomised. In 20 men with erectile dysfunction, more desire was reported after 68% of doses against 19% of placebo doses. PMID 11035391
Is well toleratedHuman, non-randomised. Nausea and yawning were frequent in the small human studies, and 12.9% had severe nausea at the dose studied. PMID 11035391
Is safe for moles and skinNo study found. No controlled study has examined its effect on existing moles; published case reports describe melanoma and changing moles in users, some in their early twenties. PMID 24355990
The reasoning behind each grade, study by study, is in this guide's Benefit & Outcome Review.
Grades checked Oct 5, 2026
A printable reference sheet with the compound's key facts, storage guidance and a vial record comes with All-Access Lifetime.
Half-life & pharmacokinetics
No human pharmacokinetic study of Melanotan II is indexed in PubMed, and the half-life figure attached to this compound across the market does not come from a measurement of it. Checked on 2026-09-10: a PubMed search for Melanotan II or MT-II in title or abstract combined with pharmacokinetics or half-life returns analog-design papers, radiolabelled melanoma-targeting work in mice, and one rat study — no human PK study of this molecule. What is published is Ugwu et al., Biopharmaceutics & Drug Disposition 1994;15(5):383-90 (PMID 7981427), a rat pharmacokinetic study after a single 0.3 mg/kg intravenous dose, and that paper's own conclusion is a caution about the half-life specifically: the terminal half-life differed depending on whether plasma was assayed by HPLC or bioassay, because a single aberrant point in the beta-phase moves it substantially when few beta-phase points are available. The nearest human figure in the literature belongs to a different molecule — Ugwu et al., Biopharmaceutics & Drug Disposition 1997;18(3):259-69 (PMID 9113347) measured melanotan-I in three human volunteers and found beta-phase plasma half-lives of 0.8 to 1.7 hours after subcutaneous dosing. That is Melanotan I, not Melanotan II. Any '30 minutes to an hour' figure quoted for Melanotan II should be treated as unsourced. What can be said without a half-life is that the pigmentation effect outlasts the compound by a wide margin: melanin, once produced, remains in the skin, and in the melanotan-I human study the tanning peaked a week after dosing ended and was still present three weeks later.
Reported side effects & toxicology
Two categories should be kept separate: what the controlled studies recorded, and what the case literature reports from unregulated use. In the three published human studies, nausea was the dominant effect — mild nausea at most dose levels in the pigmentation pilot, severe nausea after 4 of 19 injections in the organic-ED study, and severe nausea in 12.9% of subjects at 0.025 mg/kg in the pooled report — alongside facial flushing, decreased appetite, a stretching-and-yawning complex, spontaneous penile erections lasting one to five hours, and Grade II somnolence and fatigue in one subject at 0.03 mg/kg. The case literature from unregulated use is where the serious events are. Melanocytic changes are the most frequently reported: eruptive melanocytic naevi following melanotan injection (PMID 19575725), atypical melanocytic naevi (PMID 23914578), dermoscopic changes in existing naevi during use (PMID 23052015), eruptive dysplastic naevi (PMID 22425244), and melanotan-induced lentigines and naevi (PMID 21453640). Melanoma has been reported in several independent cases: melanotan-associated melanoma (PMID 21564053), melanotan-associated melanoma in situ (PMID 22724573), melanoma associated with the use of melanotan-II (PMID 24355990), oral mucosal malignant melanoma after nasal-spray use (PMID 40210573), and five primary melanomas in situ in a patient with combined melanotan, tanning-bed and anabolic-hormone exposure (PMID 42328529). Beyond the skin, published cases include priapism (PMIDs 33460908, 30796078) and priapism after overdose (PMID 23537392), systemic toxicity with rhabdomyolysis (PMID 23121206), and renal infarction (PMID 31953620). A 2017 review in the International Journal of Dermatology surveys the risks of unregulated alpha-MSH analog use as a class (PMID 28266027). None of these case reports establishes causation on its own, and case reports are a biased sample by construction — but the melanocytic findings recur across independent groups in at least five countries, which is why they are listed individually here rather than summarised. Human safety data for this compound are limited, it is unapproved, and its long-term safety is not established. This is not an exhaustive list and nothing here is medical advice.
Storage & handling
Lyophilized (powder): store sealed and protected from light; refrigeration is commonly recommended, and cool freezer storage is reported for long-term stability before reconstitution.
Reconstituted (in bacteriostatic water): keep refrigerated (about 2–8 C), protect from light, and use within a few weeks per common handling guidance.
References
Primary human record: Dorr et al., Life Sci 1996;58(20):1777-84 (PMID 8637402); Wessells et al., J Urol 1998;160(2):389-93 (PMID 9679884); Wessells et al., Urology 2000;56(4):641-6 (PMID 11018622); pooled re-report Wessells et al., Int J Impot Res 2000;12 Suppl 4:S74-9 (PMID 11035391). Pharmacokinetics: Ugwu et al., Biopharm Drug Dispos 1994;15(5):383-90 (PMID 7981427, rat); Ugwu et al., Biopharm Drug Dispos 1997;18(3):259-69 (PMID 9113347, melanotan-I in humans). Case literature: PMIDs 19575725, 21453640, 21564053, 22425244, 22724573, 23052015, 23121206, 23451671, 23537392, 23914578, 24355990, 28266027, 30796078, 31953620, 33460908, 40210573, 42328529. Identity verified against PubChem CID 92432; registry status verified against ClinicalTrials.gov record NCT07437560 on 2026-09-10. Presented for educational use only and not medical advice.
Evidence File
The Melanotan II Evidence File: Twenty Men, Three Volunteers, and a Registry Entry That Says It Is an Example
Melanotan II has a real literature — 242 indexed records with, unusually, no false positives at all. What it does not have is the clinical base its market implies. The entire human efficacy record is three volunteers for tanning and twenty men for erectile function, and one of the papers routinely counted as a fourth trial is those same twenty men reviewed a second time. Meanwhile the tanning trials most often cited for this compound were conducted on a different molecule. This file enumerates every human record, names which numbers were actually published, and opens the single registry entry that appears to be a Phase 2 trial.
242 indexed records, and zero of them are false positives
3 distinct human studies, not the 5 the publication types imply
20 men is the entire human efficacy record for erectile function
23 records carry the Case Reports type — the bulk of the human record since 2000
The census, and the finding that runs the opposite way to most peptides
The complete human efficacy record: five trial-typed records, three actual studies
The tanning trials most often cited for this compound are a different molecule
The registry entry, opened rather than counted
What has never been established, tested rather than asserted
5 more sections in the Evidence File for Melanotan II
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Melanotan II for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Sourcing File
The Melanotan II Sourcing File: An FDA-Approved Drug Sits 0.98 Daltons Away, and Low-Resolution Mass Spec Cannot Tell Them Apart
Melanotan II's closest confusable is not a knock-off. It is bremelanotide, an approved medicine, and it is this molecule's own breakdown product — one dalton heavier, sharing the second half of its InChIKey, and invisible to a nominal-mass instrument. Above that sits Melanotan I, a different molecule 622 daltons away that PubChem nonetheless lists under the bare word Melanotan. This file gives the full identifier chain re-derived from PubChem, the exact masses that separate all three, what a certificate has to resolve to be worth anything here, and the two published forensic findings about what is actually in vials sold under this name.
0.984 Da separates Melanotan II from an FDA-approved drug
The last 10 characters of both InChIKeys are identical
622.6 Da separates it from the molecule whose trials get cited for it
30% purity measured in a seized vial sold under this name
The identifier chain, re-derived from PubChem
The 0.984-dalton problem, and why it is the hardest identity check in this catalogue
The 622-dalton problem, which is easier to catch and more often missed
What has actually been found in vials sold under this name
Reading a certificate for this compound, in order
5 more sections in the Sourcing File for Melanotan II
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Melanotan II for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Benefit & Outcome Review
The Melanotan II Benefit & Outcome Review: What Twenty-Three Case Reports Say That Three Trials Do Not
Melanotan II is one of the few compounds in this library where the human safety literature is larger than the human efficacy literature — and it is the more informative of the two. Three studies in twenty-three people, all from the 1990s, established that it tans and that it produces erections, with real p-values. Everything published since has largely been case reports: rhabdomyolysis, renal infarction, priapism, encephalopathy, and a run of melanoma and pigmented-lesion reports including patients in their twenties. This review takes each claim in turn, gives the measurement behind it, and gives the counter-evidence where it exists.
2 of 3 volunteers tanned in the only pigmentation trial ever run
p=0.0045 and p=0.047 — the two real efficacy p-values, both in erectile function
12.9% of subjects had severe nausea at the studied dose
14 melanoma or pigmented-lesion case reports, including patients aged 20 and 22
Claim one: it produces tanning without sun exposure
Claim two: it produces erections and increases sexual desire
Claim three: it is well tolerated
Claim four, unstated but implied: it is safe for moles and skin
Regulatory and market context, because it bears on what a buyer is actually getting
The honest closing summary
6 more sections in the Benefit & Outcome Review for Melanotan II
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Melanotan II for $14 — or every compound in the library, plus the printable reference sheets, for $99.
Quick answers about guide scope, access, and educational use context.
Is Melanotan II approved or legal to use?
No. Melanotan II is not approved by the FDA or by regulators in the UK, EU, or other major jurisdictions for any use. It is sold as a research chemical only, and health agencies have warned against unlicensed products. This guide is educational and not an endorsement of human use.
What dose did the published human studies of Melanotan II actually use?
Every published human study dosed by body weight, subcutaneously. The 1996 pigmentation pilot started at 0.01 mg/kg and escalated to 0.025–0.03 mg/kg (PMID 8637402); both erectile-function studies used 0.025 mg/kg (PMIDs 9679884, 11018622). For a 70 kg adult, 0.025 mg/kg is about 1,750 mcg — several times the fixed amounts that circulate in community protocols. These are descriptions of published research, not recommendations.
What is the half-life of Melanotan II?
It has not been measured in humans. No human pharmacokinetic study of Melanotan II is indexed in PubMed. The '30 minutes to an hour' figure quoted across the market appears to borrow from human data on melanotan-I, a different molecule, whose subcutaneous beta-phase half-life was 0.8 to 1.7 hours in three volunteers (PMID 9113347). The only Melanotan II pharmacokinetic measurement is in rats after an intravenous dose, and that paper's own finding is that the terminal half-life was assay-dependent and unstable (PMID 7981427).
How much human evidence is there for Melanotan II tanning?
Two subjects. The only published human pigmentation study is a 1996 pilot in three normal male volunteers, of whom two showed increased pigmentation of the face, upper body and buttock by quantitative reflectance one week after a two-week dosing course ended (PMID 8637402). There is no larger human tanning study of this compound in the literature.
Has Melanotan II ever been in a registered clinical trial?
No genuine one. ClinicalTrials.gov holds exactly one record naming Melanotan II — NCT07437560, listed as recruiting with Hudson Biotech as lead sponsor — and its own brief summary opens by describing itself as an example interventional study record. A search-result count alone would report one registered trial; reading the record shows there is none.
How is Melanotan II different from Melanotan I?
Melanotan I (afamelanotide) is more selective for MC1R and is an approved drug in some regions for a rare photosensitivity disorder. Melanotan II is non-selective across melanocortin receptors, which is why it is reported to also affect appetite and sexual arousal via MC3R/MC4R, and it is not approved anywhere. The two also differ in how much human data exists: melanotan-I has published human pharmacokinetics, Melanotan II does not.
Why do community protocols use a loading phase?
The usual explanation is a short plasma half-life, but that half-life has never been measured in humans for this compound, so the reasoning is not evidence-based. What the published studies did was different again: they dosed daily by body weight for a fixed two-week course rather than loading and then maintaining. The loading-then-maintenance structure is a market convention, not a research protocol.
What are the main reported risks?
In the controlled studies, nausea dominated — severe in 12.9% of subjects at 0.025 mg/kg — along with flushing, appetite loss, prolonged spontaneous erections, and somnolence at the highest dose. The published case literature from unregulated use reports eruptive and darkening melanocytic naevi across multiple independent case series, melanoma and melanoma in situ in at least five separate reports, priapism, rhabdomyolysis with systemic toxicity, and renal infarction. Case reports cannot establish causation individually, but the melanocytic findings recur across independent groups in several countries.
Does Melanotan II darken existing moles?
Darkening of existing naevi and the appearance of new ones is the single most frequently published observation in the melanotan case literature, reported by independent groups including the first two Swedish cases (PMID 23451671), a dermoscopic follow-up series (PMID 23052015), and reports of eruptive and dysplastic naevi (PMIDs 19575725, 22425244). Because melanoma has also been reported in melanotan users, changes in pigmented lesions are the reason this compound appears in the dermatology literature at all.
Why does Melanotan II cause nausea and yawning?
Both trace to the same non-selectivity that makes the molecule work on pigment. Melanotan II agonises MC3R and MC4R in the central nervous system as well as MC1R in the skin, and the central melanocortin receptors mediate appetite and autonomic effects. In the published studies the stretching-and-yawning complex correlated with the onset of spontaneous erections one to five hours after dosing (PMID 8637402), which is why these effects appear together rather than separately.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
A certificate of analysis (COA) is a laboratory’s report on one sample of one batch. The single most useful thing to know about it is that purity and identity are two separate results that fail in different ways. A high purity figure says the sample was mostly one substance; it does not say that substance was Melanotan II. Identity — normally a mass-spectrometry result matching the expected molecular weight — is what establishes what the material actually is, and a certificate reporting purity alone has not answered that question.
Two further limits are worth holding onto. Mass per vial is its own test: a vial can be 99% pure and still contain less material than the label claims. And sterility, endotoxin, heavy metals and residual solvent screening are separately commissioned tests, usually priced individually — so a “third-party tested” badge asserts none of them unless the certificate names them. Check that the batch or lot number on the document matches the vial in front of you; an unmatched certificate describes someone else’s material.
Medibact does not test, endorse or resell peptides, and publishes no rating of any laboratory. How to read a peptide certificate of analysis walks through the document section by section, and what each COA field establishes covers the field-by-field detail and the laboratories that publish their methods.
You’ll need bacteriostatic water
The diluent for reconstituting Melanotan II
Reconstitution is volume arithmetic — it assumes a lyophilized vial is dissolved in bacteriostatic water, which is sterile water preserved with 0.9% benzyl alcohol. The preservative is what allows a vial to be entered more than once; plain sterile water carries none and is single-entry by design. Medibact supplies USP-grade Bacteriostatic Water for Injection in a 30 mL multi-dose vial, made in the United States and shipped from the United States, for research use only. One 30 mL vial covers 30 reconstitutions at 1 mL each, 15 at 2 mL, or 10 at 3 mL — division only, not a dosing recommendation.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
